Pharma BD Deal Intelligence

Hologic, Inc. / Gen-Probe Incorporated

2012 · Acquisition/Merger · $3.8B · Complete

Strongly positive — critic reaction at announcement

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 10

Hologic acquired Gen-Probe for $82.75 per share in cash (approximately $3.7 billion announced, $3.8 billion net purchase price at close). The deal combined Hologic's women's health diagnostics with Gen-Probe's leading molecular diagnostics platforms (TIGRIS, PANTHER) and APTIMA STD testing franchise.

Key facts

Announced Apr 30, 2012
Closed Aug 01, 2012
Deal value $3.8B
Deal type Acquisition/Merger
Therapeutic area Infectious Disease, Oncology, Women's Health
Key assets TIGRIS automated platform, PANTHER automated platform, APTIMA STD test franchise, PROCLEIX blood screening products
Mechanism Nucleic acid amplification testing (NAAT), Transcription-mediated amplification (TMA)

Related deals — scored

Deal	Year	Value	Outcome
Hologic, Inc. / Gen-Probe Incorporated (this deal)	2012	$3.8B	78
Hologic, Inc. / Third Wave Technologies, Inc.	2008	$580M	36
Hologic, Inc. / Cynosure, Inc.	2017	$1.6B	12
Pfizer Inc. / BioNTech SE	2020	$748M	100
Gilead Sciences Inc. / Pharmasset Inc.	2011	$11.2B	98
Abbott Laboratories / Alere Inc.	2016	$5.8B	95
bioMerieux SA / BioFire Diagnostics Inc.	2013	$485M	88

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2012 deals · Hologic, Inc. deals · Infectious Disease deals